Đánh giá hiệu quả và độc tính của thuốc ức chế tyrosine kinase trong điều trị ung thư phổi không tế bào nhỏ giai đoạn tiến xa

Evaluation of the result of first - line treatment and toxicity of Tyrosine kinase inhibitors in patients with advanced stage non - small cell lung cancer with EGFR mutations. Methods: We conducted a prospective and retrospective descriptive study on 57 patients with stage IIIB/IIIC/IV non - small cell lung cancer, treated with 1st generation Tyrosine Kinase inhibitors at Hue Central Hospital and Hue University Hospital from 01/2020 - 06/2023. Results: The complete response rate was 1.8%; the partial response rate was 45.6%; the stable disease rate was 21.1%; the progressive disease rate was 31.6%. The objective response rate was 47.4%; the disease control rate was 68.5%. Median progression - free survival was 9.0 ± 0.8 months, the shortest being 3 months, and the longest being 28 months. There was a statistically significant relationship between PFS and EGFR mutations (p < 0.05). Most patients have grade I, II toxicity and are mainly found on skin - mucosa and digestive system. Conclusion: Tyrosine Kinase inhibitors in the treatment of advanced stage non - small cell lung cancer are effective, improving survival time for patients with a well - tolerated toxicity.